Intervention: Dexamethasone phosphate
Trial phase: Phase 2
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COP(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by transcleral iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
Eligibility criteria:
Inclusion Criteria:

Undergoing unilateral cataract extraction and implantation of a monofocal IOL (at the time of enrollment)
Male or female 18 years or older
Receive, understand, and sign a copy of the written informed consent form
Be able to return for all study visits and willing to comply with all study-related instructions

Exclusion Criteria:

Subjects not meeting the inclusion criteria
Subjects being implanted with a multifocal IOL
Ocular surgery of any kind in the study eye within 6 months prior to baseline visit
Cataract surgery on the fellow eye within 6 weeks, including 2 weeks without topical ocular medication, prior to baseline visit
Scheduled for surgery in the fellow eye within the study period
Have anterior chamber inflammation as measured by slit lamp examination at baseline. Anterior chamber cell and/or flare grade > 0
Have used any topical ocular medication in either eye, other than tear substitute for dry eye, at least 2 weeks prior to baseline visit
Have IOP ≥ 25 mmHg at baseline, a history of glaucoma, or require ocular anti-hypertensive medications
Be known corticosteroid intraocular pressure responder in either eye
Have used topical corticosteroid or NSAID treatment in either eye ≤ 48 hours prior to baseline visit
Systemic administration of corticosteroid within the past 14 days prior to baseline visit
Have received intravitreal, sub-Tenon's, or any periocular corticosteroid treatment in either eye within the past 6 months prior to baseline visit
Have open wounds/ skin disease on the forehead area where the iontophoresis return electrode will be applied
Have severe lesions of the eyelids or the ocular surface impeding the application of the iontophoresis applicator
Have blepharospasm, blepharophimosis, or other eyelid anatomic variations precluding the placement of the iontophoresis applicator
Have significant Fuch's Corneal Dystrophy
Have known allergy to dexamethasone or dexamethasone phosphate or any medication to be used in this study
Have history or diagnosis of ocular herpes, corneal lesion of suspected herpetic origin
Have optic neuritis of any origin
Have clinically suspected or confirmed central nervous system or ocular lymphoma
Have active hyphema, pars planitis, choroiditis, Behçet's disease, clinically significant macular edema, toxoplasmosis scar, or vitreous hemorrhage
Have severe/serious ocular pathology or medical condition which may preclude study completion
History of HIV/AIDS
Have pacemaker and/or any other electrical sensitive support system
Be pregnant or lactating female, or female of childbearing age and using inadequate birth control method
Have participated in another investigational device or drug study within 30 days of baseline visit
Have already participated in this study